PropThink: Dendreon Q3 Earnings Preview: Can the Company Overcome the Odds?
(Thomson Reuters ONE) -
By Ivan Deryugin
One of the most controversial companies in the biotechnology sector today is
Dendreon (NASDAQ:DNDN). To some, the company represents the worst of Wall
Street, an overhyped company with an overhyped product that has cost investors
huge sums of wealth. And to others, Dendreon is a company that is deeply
misunderstood, and whose true value has yet to be realized. Since the company
went public over a decade ago, its stock has been a battlefield between these
two opposing forces.
Dendreon's stock soared from 2009 to 2011 as optimism regarding Provenge, the
company's unique prostate cancer therapy, grew. And the stock fell sharply as
that optimism proved to be excessive. Dendreon has failed to ramp up sales of
Provenge in a meaningful way, and the results of that can be seen in the stock's
chart, shown above. But, with shares hovering near $4, has the pessimism
surrounding Dendreon become too much? With over 30% of the company's float sold
short, the situation is ripe for a short squeeze. And with the company set to
report Q3 2012 earnings on October 30, there may be an opportunity for traders
to profit.
Setting the Stage
If an investor were to look at Dendreon's results for Q2 2012, and they had
never heard of the company, they would be likely to assume that the company is
on the right path. After all, sales of Provenge came in at $79.964 million, up
66.11% from a year ago. And the company's net loss narrowed to 65 cents per
share, down from 79 cents a year ago. But, if that investor were to look at
expectations for Provenge when it was launched, they would likely be
disappointed. For fiscal 2012, the current consensus forecast calls for Dendreon
to post a loss of $2.64 per share.
While that may not be outrageous for a biotechnology company in the process of
launching a new product, Dendreon was expected to be posting solid profits by
now back when Provenge was first launched. Earnings forecasts for Dendreon had
called for earnings of almost $2 per share for fiscal 2012 back in 2010, and
they have been steadily declining ever since.
As Medivation (NASDAQ:MDVN) and Johnson & Johnson (NYSE:JNJ) have launched their
own prostate cancer therapies, Xtandi and Zytiga, many investors see them as
being the death knell of Dendreon. However, it may be too early to write the
company off. CEO John Johnson is working hard to turn the company around, and
the company's Q3 results will allow him and his team to update investors on
their restructuring efforts, and where Provenge stands in the market.
Q3 Earnings: Things to Watch For
The Reuters consensus forecast is for Dendreon to post a loss of 86 cents per
share in Q3. And while the headline numbers (both for EPS and sales of Provenge)
are important, they are not what investors need to be focused on. Right or
wrong, Dendreon faces a large amount of doubt regarding its ability to survive
as a standalone company, and the company needs to disprove such doubts on its Q3
conference call. Specifically, there are 4 issues that need to be addressed:
1. Sales force turnover: On its Q2 call, Dendreon admitted that increasing
turnover in its sales force had negatively affected results. CEO John Johnson
stated that sales in markets where there was significant turnover saw sales drop
30% sequentially relative to markets without such turnover issues. He stated
that there should be stabilization in the third quarter, and he should provide
an update on this issue when Q3 earnings are released. Credit Suisse (which has
a neutral rating and $6 price target on the stock) says that thisissue is
fixable, but that the "window is closing." Because of the complex logistics of
infusing Dendreon, the firm believes that physicians need more assistance from
Dendreon than they would if it was a simpler drug, and that if the company is
unable to fix the issues within its sales force, that physicians may simply move
on from choosing to utilize the drug.With Xtandi now approved, and Bayer set to
file for approval of its own prostate cancer drug by the end of 2012, there may
be increased "poaching" of Dendreon sales representatives, an issue that the
company needs to prevent.
2. Competition: Perhaps the biggest issue facing Dendreon is the assumption that
Provenge is inferior to other prostate cancer therapies. Analysts put pressure
on Dendreon's executives on its Q2 conference call to discuss the impact that
Zytiga had on the quarter's results, and now that Xtandi is approved, and with
Zytiga's PDUFA date for pre-chemotherapy use of December 15 fast approaching,
this pressure is likely to intensify. Dendreon, from CEO John Johnson on down,
needs to unequivocally reiterate its view that Dendreon is a complimentary
therapy, and that these new prostate cancer drugs are not competitors, but
rather partners in the goal of fighting prostate cancer. Joe DePinto, Dendreon's
head of commercial operations, stated this multiple times on the company's last
conference call:
"We see this product [Zytiga] as complementary, we see them to be used as more
and more therapies come out in this space. Patients will be able to have the
benefit of multiple therapeutic options and we see the importance of the
sequencing and what's occurring in sequencing out in the market both at the
podium, at major meetings, as well as what we are hearing when we talk to
physicians as being an important component. We also believe that in that
sequencing story Provenge as an immunotherapy should be sequenced up front prior
to Zytiga. We are also seeing in the marketplace is that as competitors or
additional products enter this space, the noise increases, more patients get
screened and this is better for patients and also better for us, because those
are the patients that are identified earlier at asymptomatic patients that would
be ideal to start on Provenge therapy."
As more men receive screenings for prostate cancer, thanks to increased
awareness, more cases can be caught early, the ideal time for Provenge to be
used. Dendreon needs to make this point clear, and also tell both analysts and
investors that the physicians using Provenge are using it in conjunction with
other therapies. Aetna (NYSE:AET) recently expanded coverage, citing the medical
necessity of Provenge in patients where their prostate cancer has spread, but
not yet reached the liver. CEO John Johnson also stated that Zytiga did not take
share from Provenge in the pre-chemotherapy market, and that the issues the
company saw in Q2 were internal in nature, and therefore fixable. Continue
reading by clicking here.
See This Article in Full at PropThink.com.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1652389]
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2012 - 15:17 Uhr
Sprache: Deutsch
News-ID 196339
Anzahl Zeichen: 9440
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: Dendreon Q3 Earnings Preview: Can the Company Overcome the Odds?"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
